Different SGLT2 inhibitors have been approved by the European Medicines Agency (EMA) and the Food and Drug Administration (FDA) for the management of glycemic control in patients with type 2 diabetes [9]. This evidence concerns the gene SLC5A2 and type 2 diabetes mellitus.